12:00 AM
 | 
Jul 15, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Januvia sitagliptin regulatory update

Germany's Institute for Quality and Efficiency in Healthcare (IQWiG) issued a preliminary benefit assessment saying that a non-fixed combination of Merck's Type II diabetes drug Januvia sitagliptin and metformin had varying degrees of additional benefit, depending on the specific patient population, over sulfonylurea and metformin. IQWiG said that the combination has a "marginal" additional benefit over sulfonylurea and metformin in patients for whom a near-normal blood sugar level...

Read the full 319 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >